# A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers

> **NCT04223895** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 30 (estimated)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** CKD-386 Formulation 1
- **DRUG:** CKD-386 Formulation 2
- **DRUG:** D012, D326 and D337

## Key facts

- **NCT ID:** NCT04223895
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-01
- **Primary completion:** 2020-03-04
- **Final completion:** 2020-06-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04223895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04223895, "A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04223895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*